New York, New York--(Newsfile Corp. - November 12, 2025) - If you suffered a loss on your Inspire Medical Systems, Inc. (NYSE: INSP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/inspire-medical-systems-inc-lawsuit-submission-form?prid=176930&wire=5&utm_campaign=3or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareho ...

INSP SHAREHOLDER ALERT: BFA Law Notifies Inspire Medical Systems, Inc. Investors of Important January 5 Securities Class Action Deadline for Investors seeking RecoveryNovember 12, 2025 7:17 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 12, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period, highlighting potential misrepresentation regarding the market demand for its sleep apnea device, Inspire V [2][6]. Group 1: Class Action Details - The class action lawsuit pertains to purchases made between August 6, 2024, and August 4, 2025, and aims to address alleged misrepresentations by the company regarding the demand and launch of the Inspire V device [2][6]. - Investors who purchased Inspire Medical common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. Group 2: Legal Process and Participation - Interested investors can join the class action by submitting a form or contacting the law firm directly, with a deadline to serve as lead plaintiff set for January 5, 2026 [4][7]. - It is noted that no class has been certified yet, meaning investors are not represented by counsel unless they retain one [8]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has consistently ranked highly in terms of securities class action settlements and has recovered hundreds of millions of dollars for investors over the years [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a proposed class-action lawsuit for allegedly misleading investors regarding the commercial readiness and demand for its Inspire V sleep apnea device, leading to a significant stock decline [1][6]. Company Overview - Inspire Medical Systems, Inc. is under investigation by prominent investor rights law firm Hagens Berman for claims related to investor losses during the class period from August 6, 2024, to August 4, 2025 [2][3]. Allegations and Claims - The lawsuit asserts that Inspire provided repeated assurances about meeting all regulatory and commercial prerequisites for the Inspire V launch, while claiming high demand and successful commercial proceedings [3]. - Contrary to these assurances, the lawsuit claims that the Inspire V launch was a failure, with minimal initial demand due to customers being overstocked with the older Inspire IV devices [4]. - The complaint indicates that Inspire neglected essential steps to facilitate the new device's adoption by clinicians and payors [4]. Impact of the Launch - On August 4, 2025, Inspire disclosed that the launch faced an "elongated timeframe" due to undisclosed challenges, including incomplete training and onboarding at many centers [5]. - The company noted that while the CPT code for Inspire V was approved for Medicare patients, necessary software updates for claims processing were delayed until July 1, affecting billing capabilities [5]. - Demand for Inspire V was further hindered by the need for customers to deplete existing Inspire IV inventory, which is expected to continue impacting demand [6]. Financial Consequences - Following the disastrous launch, Inspire slashed its 2025 earnings guidance by 80%, projecting earnings of only $0.40 to $0.50 per share [6]. - The announcement led to a significant drop in Inspire's stock price, with shares falling by approximately 32%, or $42.04, the day after the news [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged violations of federal securities laws during the Class Period from August 6, 2024, to August 4, 2025, seeking to recover losses for investors [1][3]. Company Overview - Inspire Medical develops and manufactures an implantable medical device for obstructive sleep apnea known as Inspire, with the latest version, Inspire V, designed to improve respiration during sleep [4]. Lawsuit Details - The lawsuit, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., alleges that the company and certain senior executives made false and misleading statements and failed to disclose critical issues regarding the Inspire V rollout [3][4]. - On August 4, 2025, Inspire Medical disclosed that the rollout of Inspire V faced an "elongated timeframe" due to undisclosed issues, including delays in software updates for billing Medicare patients, which only took effect on July 1, 2025 [4]. - The company acknowledged that demand for Inspire V was negatively impacted by excess channel inventory, leading to a reduction in its 2025 earnings guidance by more than 80% [4]. Stock Performance Impact - Following the negative disclosures, Inspire Medical's stock price declined by more than 32%, resulting in significant losses for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, with the case titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations and Stock Impact - The lawsuit alleges that Inspire misled investors by claiming it had taken necessary steps for the launch of Inspire V, while in reality, it failed to prepare clinicians and payors, leading to delays and weak demand [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, attributing this to undisclosed factors [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Points - A class action has been filed against Inspire Medical Systems, Inc. for allegedly misleading investors regarding the Inspire V device launch [1][2] - The Inspire V device is intended for treating obstructive sleep apnea and was marketed as a groundbreaking product [2] - The launch of Inspire V faced significant challenges, including poor demand and inadequate preparation by the company [3] Allegations - Inspire Medical Systems failed to complete essential tasks for the successful launch of Inspire V, such as training for treatment centers and updating IT systems [3] - The company did not ensure that Medicare reimbursement was in place at the time of the launch, which contributed to the launch's difficulties [3] Financial Impact - On August 4, 2025, Inspire revealed that the launch was facing an "elongated timeframe," leading to a drastic reduction in 2025 earnings guidance by over 80% [4] - Following this announcement, the stock price plummeted by $42.04 per share, a decline of more than 32%, resulting in a loss of $1.2 billion in market capitalization in one day [4] - From a high of $216.71 per share on September 23, 2024, the stock price dropped nearly 60%, erasing billions from the company's market capitalization [4]

Core Viewpoint - Glancy Prongay & Murray LLP has initiated an investigation into Inspire Medical Systems, Inc. regarding potential violations of federal securities laws affecting investors [1] Company Summary - The investigation is focused on Inspire Medical Systems, Inc. (NYSE: INSP) and concerns possible legal claims for investors who have incurred financial losses [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of misleading statements regarding the launch and demand for its Inspire V device, which has led to significant financial losses for investors [2][5][8]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Inspire Medical to contact them for legal options [1]. - There is a deadline of January 5, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Inspire Medical [2]. Group 2: Allegations Against Inspire Medical - The complaint alleges that Inspire Medical and its executives violated federal securities laws by making false statements about the market demand for the Inspire V device and the company's readiness for its launch [5]. - Inspire Medical announced on August 4, 2025, that the launch of the Inspire V device faced significant delays due to incomplete training and onboarding at treatment centers, as well as billing and reimbursement challenges [6]. Group 3: Financial Impact - Following the announcement of setbacks, Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [8]. - The stock price of Inspire Medical fell over 32% in one day, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [8].

Core Points - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud [1] Company Summary - The lawsuit indicates potential legal challenges for Inspire Medical Systems, Inc. related to allegations of securities fraud [1]